Telesis Bio, Inc. (NASDAQ:TBIO) Short Interest Update

Telesis Bio, Inc. (NASDAQ:TBIO) was the target of a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 2,900 shares, a decrease of 84.2% from the May 15th total of 18,300 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average trading volume of 3,100 shares, the short-interest ratio is currently 0.9 days.

Telesis Bio Price Performance

Shares of TBIO opened at $0.05 on Friday. The firm has a 50-day moving average price of $0.34 and a 200 day moving average price of $0.38. The firm has a market capitalization of $90,100.00, a PE ratio of 0.00 and a beta of 1.42. Telesis Bio has a 52-week low of $0.01 and a 52-week high of $6.17.

About Telesis Bio

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.